DINALBEN PATEL: Open Payments
NPI 1851858971 · PLANO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,345 in 56 payments from 14 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $1,345
Food & beverage: $1,345
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $418 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $174 |
| Ardelyx, Inc. | 6 | $110 |
| Janssen Biotech, Inc. | 3 | $93 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $92 |
| GENZYME CORPORATION | 4 | $90 |
| Regeneron Healthcare Solutions, Inc. | 3 | $89 |
| Madrigal Pharmaceuticals | 3 | $74 |
| QOL Medical, LLC | 3 | $71 |
| Aimmune Therapeutics, Inc. | 3 | $63 |
Products named: SKYRIZI, XIFAXAN, RINVOQ, DUPIXENT, IBSRELA, TREMFYA, REZDIFFRA, Sucraid.
Industry payments across TX — which companies pay providers there.
